Patient focus is at the core of everything we do at Bristol Myers Squibb (BMS). We are committed to transform the lives of patients with our Innovative therapies. Our customized Patient Support Programs (PSP) are one of the stepping stones of enhancing access to our innovative therapies and ensuring that our medicines are available to those who need them most.
Patient Support Program platform is developed by Health Lane Technologies (Zelthy – System Partner) and executed by Health Care at Home (HCAH - PSP Vendor Partner of Bristol Myers Squibb, India). PSP is currently available for Opdyta (Nivolumab) and Rojuzda (Luspatercept)
On prescription of Health Care Professional (HCP) for indications that are approved in India, patients can voluntarily enrol to PSP and avail access to therapy basis the terms and condition as defined for PSP. Program is applicable for patients who do not have any form of full reimbursement.